Member Info for stephen11

I’ll track back on this when my schedule permits, but have Kodal mentioned, in any of the investor meetings, a rough date that we might expect some gold drill results?

This sleeping 😴 giant has just woken up

The funding for the FDA doesn’t necessarily need to be from a placing, as eluded to in the last investmeetcompany presentation.

A JV with an American based company, an upfront commission based sales/partnership agreement, or loans could all be among a handful of options.

Indeed, someone once added especially if it’s your own blood 🩸. Silly not to add to your holdings at these levels 😊

Anyone else struggling to get a live quote to buy this morning, or maybe its just like that on Hargreaves Lansdown?

It’s a good analogy for this share at times, except it’s the faithful who will be handsomely rewarded 😊, very soon.

Well said Bighammer 😊

Allguessing,

I respectfully disagree with your previous comment.

Babies born premature and those born with underlying health conditions are extremely fragile. There state of health can change in a matter of minutes or even seconds.

It is entirely logical that babies should be tested for adverse antibiotic reactions when being admitted to the ward. Then, if antibiotics are needed the correct medication can be administered in a timely fashion.

GLA.

Stephen11.

Also, lets not forget that the test provides information through the maternal line i.e., if i remember correctly the mother and any future siblings would also be allergic to aminoglycoside.

This would indeed support the health economics of all preterm babies being tested.

Its a shame we didn't have an investmeetcompany presentation coming shortly - these and similar questions could then be fielded to James Cheek.

GLA.

Stephen11.

Good info sharing Rud20 and thankyou - please post more often

I suppose it makes good sense if all preterm babies be tested on arrival, meaning that the correct antibiotics could be administered in a timely manner if needed. This model would significantly increase revenues.

Good question as to whether or not this is new. I had previously believed only the infants that needed an antibiotic were tested - I’ll do some more digging on this when time permits.

Maybe some of the other long term holders would have a view on this?

Stephen11.

Could be 39p by the end of January - stranger things have happened in this share throughout the last 4 years.

Cheers john, Bighammer, and Eureka - great info sharing.

Your point 4 is most relevant for the MTRNR-1 Eureka - "best value for patients and taxpayers." The hearing loss assay prevents lifelong hearing loss and the need for Cochlear implants.

That said, forget about the shareprice for a moment - for those premature babies, that get treated with the correct medication because of this test, this is lifechanging.

I have healthy twin daughters who were born premature some years ago myself, and received exceptional care and treatment in a neonatal ward.

For these reasons i'll always be a firm GDR supporter.

GLA.

Stephen11.

So, how is the new CEO doing - lets have a look at what has been achieved and what we can look forward to!

*****The Future - Near Term*****

- James said: Revenue and commercial traction for the hearing loss test imminent - as soon as Dec 23 and Jan 24 (Brighton adopted the test and came live in December 4th 2023, and we now hear of the possibility that the 11 neonatal units in Kent, Surrey, and Sussex should go live soon. Additionally, as per 20th Dec RNS, initial overseas orders have been received from France, Austria, Greece, Saudi Arabia, Turkey and the Netherland) - i'd say that's pretty good progress from a man who has kept his word

- 100% clarity from the new CEO that special commissioning for the hearing loss test will happen - we'll watch this space, but momentum appears to be growing

- Contracts being drawn up with potential partners who can help with the FDA application for the hearing loss product in a cost effective manner - hope we hear about this soon

- NICE full validation for the MTRNR1 is being hindered by the EVO procedure and not the product - news due Jan 2024

- NICE Review of the CYP2CI9 - due Jan 2024

- More grant funding is also a possibility e.g., through MedTech etc.

*****Funding*****

- Funding: Q1 2024 - funding will be specifically for FDA of the MTRNR1 - RF drawdowns, sales, and tax credits will cover the monthly cash burn, despite what the derampers say!

- I must remind everyone that Q1 runs to the 31st March 2024, so funding for FDA doesn't necessarily need to be imminent. Additionally, other funding options are available for FDA, such as a JV or some form of American partner deal, as JC eluded to

GLA.

Stephen11.

As Jimmy said earlier, they will probably announce 📣 it when the staff training is completed and the various sites go live, as with Brighton.

Interesting conversation thread this morning, but to add balance, take note of what James Cheek said about the specialist commissioning of the MTRNR1 Test - the "100% clarity its happening" comment in particular.

From 23 minutes onwards in the GDR investormeetcompany presentation James Cheek is speaking about early adoption of the MTRNR1 hearing loss test through the NHS Special Commissioning programme.

He states "Pretty much got absolute 100% clarity that it is happening...big driver is to make sure it happens as quickly as possible." For the cynics amongst you, please listen to the presentation.

What is Special Commissioning? (info taken from NHS website)

- Special Commissioning is used to ensure smaller population have access to adequate medical provision to meet their specific needs. The population size can be as low as a few thousand or as many as 100,000

* Massive tick for GDR as there are 60,000 premature babies born in the UK per year

- Certain cohorts of the products and populations are prioritised for special commissioning. These include babies, infants, and children

* Massive tick for GDR

- The NHS 2022/23 budget for special commissioning was 22.9 billion and is increasing in 2023/23

* Massive tick for GDR

In a de facto manner Special Commissioning could be as good as full NICE accreditation.

GLA.

Stephen11.

Well said that man Pubsshut 👍

As James Cheek spoke about at the investmeetcompany meeting ‘Specialist Commissioning’ will happen for the MTRNR-1 hearing product.

Thanks John - that’s quite a large and densely populated area: Kent, Surrey, and Sussex - I’ll dig around later to see how many specialist neo-natal units the trust has and feedback to this forum.

Agreed Stims - word is spreading in the medical community and things are starting to happen 😊.

The ripple effect is starting - fantastic news 😊.

Ps…what is KSS the abbreviation for?

GLA.

Stephen11.

Great to see GDR actively marketing in the Middle East - the phrase follow the money 💰 springs to mind 😊.